Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02838979 · ClinicalTrials.gov registry record · Phase 2
Trial of Oral Glutamine on Mitochondrial Function in CKD
A Phase 2 study of Cardiovascular Disease and Endothelial Dysfunction, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT02838979: Completed Phase 2 study of Cardiovascular Disease and Endothelial Dysfunction, sponsored by University of Washington.
NCT02838979 is a Phase 2 study of Cardiovascular Disease and Endothelial Dysfunction that has completed, run by University of Washington. The registered enrollment target is 11 participants, below the 2,697-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02838979, a Phase 2 study of Cardiovascular Disease and Endothelial Dysfunction, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary goal of proposed investigation is to study the impact of oral glutamine supplementation on muscle mitochondrial and endothelial cell function measured mitochondrial energetics and vascular function using 31P magnetic resonance spectroscopy and optical spectroscopy (MRS/OS) among persons with moderate-severe CKD. The secondary objective is to describe the impact of oral glutamine supplementation on mitochondrial metabolic profile as well as inflammatory and oxidative stress biomarkers among persons with chronic kidney disease.
Primary Outcome
31P MRS/OS was used to measure mitochondrial phosphorylation capacity (ATPmax).
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT First Intervention (14 days)
- OTHER Washout (3 weeks)
- DIETARY_SUPPLEMENT Second Intervention (14 days)
Study Locations (1)
Washington
- Kidney Research Institute, University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2016-02-25 |
| Est. Completion | 2018-01-31 |
| Phase | Phase 2 |
What the finished NCT02838979 record still lists
NCT02838979 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 2,697-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (100% lower).
The record links to 5 conditions, with Cardiovascular Disease appearing as the primary indexed condition, and to 3 interventions - of which First Intervention (14 days) is the first listed.
NCT02838979 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT02838979 about?
NCT02838979 is a clinical study titled "Trial of Oral Glutamine on Mitochondrial Function in CKD". The primary goal of proposed investigation is to study the impact of oral glutamine supplementation on muscle mitochondrial and endothelial cell function measured mitochondrial energetics and vascular function using 31P magnetic resonance spectroscopy and optical spectroscopy (MRS/OS) among persons ...
What is the current status of trial NCT02838979?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2016-02-25. Estimated completion is 2018-01-31.
What conditions does trial NCT02838979 study?
This clinical trial studies the following conditions: Cardiovascular Disease, Endothelial Dysfunction, Sarcopenia, Kidney Disease, Muscle Mitochondrial Function.
What interventions are being tested in trial NCT02838979?
The interventions under investigation include: First Intervention (14 days) (DIETARY_SUPPLEMENT), Washout (3 weeks) (OTHER), Second Intervention (14 days) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02838979?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02838979 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02838979's enrollment target sits among peer trials
11 137th of 137 higher than 1 of 137 other Cardiovascular Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults
RECRUITING · Phase 2
-
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
RECRUITING · Phase 2
-
Metformin in Kidney Disease
COMPLETED · Phase 2
-
Biomarker Guided Therapies in Stage A/B Heart Failure
COMPLETED · Phase 2
-
Reduction of Smoking in Cardiac Disease Patients
COMPLETED · Phase 2
-
The Fibrin Pad Cardiovascular Study
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI